Literature DB >> 27903676

hERG Channels: From Antitargets to Novel Targets for Cancer Therapy.

Annarosa Arcangeli1, Andrea Becchetti2.   

Abstract

In this issue of Clinical Cancer Research, evidence is provided on how to avoid cardiotoxicity when targeting hERG K+ channel for cancer therapy. hERG regulates different aspects of neoplastic progression. Although its blockade has effective anticancer effects in experimental models, it may lead to fatal arrhythmias in humans. Clin Cancer Res; 23(1); 3-5. ©2016 AACRSee related article by Pointer et al., p. 73. ©2016 American Association for Cancer Research.

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27903676     DOI： 10.1158/1078-0432.CCR-16-2322

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   12.531


  14 in total

1.  Assessing hERG1 Blockade from Bayesian Machine-Learning-Optimized Site Identification by Ligand Competitive Saturation Simulations.

Authors:  Mahdi Mousaei; Meruyert Kudaibergenova; Alexander D MacKerell; Sergei Noskov
Journal:  J Chem Inf Model       Date:  2020-11-16       Impact factor: 4.956

2.  MicroRNA 362-3p Reduces hERG-related Current and Inhibits Breast Cancer Cells Proliferation.

Authors:  Abdullah A Assiri; Noha Mourad; Minghai Shao; Patrick Kiel; Wanqing Liu; Todd C Skaar; Brian R Overholser
Journal:  Cancer Genomics Proteomics       Date:  2019 Nov-Dec       Impact factor: 4.069

3.  Influence of Kv11.1 (hERG1) K+ channel expression on DNA damage induced by the genotoxic agent methyl methanesulfonate.

Authors:  Sara Fernández-Villabrille; Enol Álvarez-González; Francisco Barros; Pilar de la Peña; Luisa María Sierra
Journal:  Pflugers Arch       Date:  2021-01-15       Impact factor: 3.657

Review 4.  Natural products modulating the hERG channel: heartaches and hope.

Authors:  Jadel M Kratz; Ulrike Grienke; Olaf Scheel; Stefan A Mann; Judith M Rollinger
Journal:  Nat Prod Rep       Date:  2017-08-02       Impact factor: 13.423

Review 5.  Ion channels as therapeutic antibody targets.

Authors:  Catherine J Hutchings; Paul Colussi; Theodore G Clark
Journal:  MAbs       Date:  2018-12-10       Impact factor: 5.857

6.  Generation and characterization of novel recombinant anti-hERG1 scFv antibodies for cancer molecular imaging.

Authors:  Claudia Duranti; Laura Carraresi; Angelica Sette; Matteo Stefanini; Tiziano Lottini; Silvia Crescioli; Olivia Crociani; Luisa Iamele; Hugo De Jonge; Ermanno Gherardi; Annarosa Arcangeli
Journal:  Oncotarget       Date:  2018-10-09

Review 7.  Role of ion channels in gastrointestinal cancer.

Authors:  Kyle J Anderson; Robert T Cormier; Patricia M Scott
Journal:  World J Gastroenterol       Date:  2019-10-14       Impact factor: 5.742

8.  Mechanism of hERG inhibition by gating-modifier toxin, APETx1, deduced by functional characterization.

Authors:  Kazuki Matsumura; Takushi Shimomura; Yoshihiro Kubo; Takayuki Oka; Naohiro Kobayashi; Shunsuke Imai; Naomi Yanase; Madoka Akimoto; Masahiro Fukuda; Mariko Yokogawa; Kazuyoshi Ikeda; Jun-Ichi Kurita; Yoshifumi Nishimura; Ichio Shimada; Masanori Osawa
Journal:  BMC Mol Cell Biol       Date:  2021-01-07

9.  miR-493 inhibits proliferation and invasion in pancreatic cancer cells and inversely regulated hERG1 expression.

Authors:  Duo Zhi; Xin Zhao; Mei Dong; Caichuan Yan
Journal:  Oncol Lett       Date:  2017-10-12       Impact factor: 2.967

Review 10.  The Sigma-1 Receptor: When Adaptive Regulation of Cell Electrical Activity Contributes to Stimulant Addiction and Cancer.

Authors:  Olivier Soriani; Saïd Kourrich
Journal:  Front Neurosci       Date:  2019-11-12       Impact factor: 4.677
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.